Caricamento...
Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4094627/ https://ncbi.nlm.nih.gov/pubmed/25045252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S38142 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|